Risk of HIV-1 infection (vaccine vs placebo), adjusted for herpes simplex virus 2 status at Phambili enrollment, within subgroups.
- Zoe Moodie (211088)
- Barbara Metch (189683)
- Linda-Gail Bekker (60754)
- Gavin Churchyard (321321)
- Maphoshane Nchabeleng (325727)
- Koleka Mlisana (72866)
- Fatima Laher (238017)
- Surita Roux (325732)
- Kathryn Mngadi (795219)
- Craig Innes (662182)
- Matsontso Mathebula (325737)
- Mary Allen (742378)
- Carter Bentley (795220)
- Peter B. Gilbert (30581)
- Michael Robertson (791255)
- James Kublin (325740)
- Lawrence Corey (140058)
- Glenda E. Gray (230796)
Publication date
September 2015
DOIAbstract
<p>HR = hazard ratio (vaccine vs placebo), adjusted for baseline herpes simplex virus 2 status. Ad5 = adenovirus serotype 5.</p><p><sup>a</sup> p-value for test of interaction for subgroup and treatment group</p><p>Risk of HIV-1 infection (vaccine vs placebo), adjusted for herpes simplex virus 2 status at Phambili enrollment, within subgroups.</p
Add to ORKG